david ettinger, md, on choosing between immunotherapy and chemotherapy in metastatic nsclc patients
Published 8 years ago • 76 plays • Length 0:25
Download video MP4
Download video MP3
Similar videos
-
0:35
david ettinger, md, talks about impact of immunotherapy in 1st line metastatic nsclc patients
-
0:46
david gandara, md, discusses considerations when choosing between immunotherapy and chemotherapy
-
0:35
david ettinger, md, on cost of therapy when choosing agents for late stage lung cancer patients
-
1:11
david ettinger, md, provides practical advice related to pd-l1 testing in metastatic nsclc patients
-
0:56
david ettinger, md, on the positioning of ramucirumab (cyramza) for nsclc
-
1:32
david gandara, md, talks about the potential impact of immunotherapy in 1st line nsclc
-
0:31
david gandara, md, discusses pembrolizumab vs docetaxel for previously treated nsclc patients
-
0:46
clinical trials in lung cancer explained video
-
2:09
dr. david carbone on the investigation of immunotherapy in lung cancer
-
2:53
immunotherapy: a revolution in cancer treatment
-
5:09
how are targeted therapy and immunotherapy used in lung cancer care?
-
0:44
mark levis, md, on importance of potency and selectivity for treating flt3 positive patients
-
0:41
julie brahmer, md, talks about the potential impact of immunotherapy in 1st line nsclc
-
1:23
alan p. venook, md, on if the resorce trial will change the role of regorafenib
-
1:11
jasgit sachdev, md, on new drugs for treating patients w/ triple negative breast cancer.
-
7:50
immunotherapy modalities
-
0:48
phil bonomi, md, discusses costs of new lung cancer therapies relative to duration of therapy
-
0:50
research into new immunotherapies for breast cancer
-
0:57
dr. choti discusses immunotherapy in pancreatic cancer
Clip.africa.com - Privacy-policy